Meeting
2023 ASCO Annual Meeting
Phase Ib/II study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) combination in metastatic melanoma refractory to prior immune checkpoint inhibitor therapy with and without CNS disease.
Authors
Saya Jacob
UCSF Hem/Onc Fellowship, San Francisco, CA
Saya Jacob , Adil Daud
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT05695898
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS9595)
DOI
10.1200/JCO.2023.41.16_suppl.TPS9595
Abstract #
TPS9595
Poster Bd #
356b
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Severe immune-related adverse effects (irAE) requiring hospital admission in patients treated with immune checkpoint inhibitors for advanced malignancy: Temporal trends and clinical significance.
First Author: Kerry Lynn Reynolds
Poster
2016 ASCO Annual Meeting
Comprehensive analysis of five key immune related adverse events (irAE) from immune checkpoint blockers (ICB) CTLA-4 and PD-1 inhibitors in cancer patients.
First Author: Guillermo de Velasco
Poster
2023 ASCO Annual Meeting
Risk of immune-related adverse events (irAE) with immune checkpoint inhibitors (ICI) in patients (pts) with family history (FH) of autoimmune disease (AID).
First Author: Piyush Grover
Poster
2022 ASCO Annual Meeting
Management of infliximab-refractory immune checkpoint inhibitor gastrointestinal toxicity: A multicenter case series.
First Author: Catriona Harvey